Business
PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
BURLINGTON, Mass., December 15, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today outlined key accomplishments from 2025 and provided an overview of strategic priorities and anticipated milestones for 2026. The Company also announced its attendance at the 44th Annual J.P. Morgan Healthcare Conferenc
About this update from Pharmaessentia Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":16834,"height":5437,"url":"https://media.zenfs.com/en/business-wire.com/6b6663bdc483bce0bde8fda0658b8699"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zcy220TUNxQJT1nk21YdrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6b6663bdc483bce0bde8fda0658b8699","width":960,"height":310},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YenPptl_MYjOvgQIGhSHVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6b6663bdc483bce0bde8fda0658b8699","width":1200,"height":388}},"lazy":false},{"type":"text","content":"Company to present at 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"Label expansion submissions for BESREMi® (ropeginterferon alfa-2b-njft) filed with FDA","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"BURLINGTON, Mass., December 15, 2025--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today outlined key accomplishments from 2025 and provided an overview of strategic priorities and anticipated milestones for 2026. The Company also announced its attendance at the 44th Annual J.P. Morgan Healthcare Conference, with a presentation scheduled for Thursday, January 15 at 10:30 a.m. PT (1:30 p.m. ET).","length":607,"tagName":"p"},{"type":"text","content":""PharmaEssentia delivered a year of substantial progress in 2025, driven by the strong performance of BESREMi® and preparation for continued growth supported by exceptional commercial execution and important pending product milestones," said Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia. "BESREMi® has become a key growth engine for our company with the potential to transform treatment across multiple patient populations living with serious myeloproliferative neoplasms (MPNs). In 2025, we saw strong performance in polycythemia vera (PV) and are well positioned for further acceleration. With our injection pen submitted...